ABEO Abeona Therapeutics Inc
10,387
$4.45
$0.05
(1.14%)
| Watchers | 10,387 |
| 52-Wk Low | $2.83 |
| 52-Wk High | $9.01 |
| Market Cap | $121.73M |
| Volume | 526,684.00 |
| 52-Wk High | $9.01 |
| 52-Wk Low | $2.83 |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEOPR Newswire • 3 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of...
Share to Feed
Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Abeona Therapeutics Inc. (Abeona or the Company...
The Law Offices of Frank R. Cruz announces an investigation of Abeona Therapeutics Inc. (Abeona or the Company) (NASDAQ: ABEO) on behalf of investors concerning the Companys possible violations of...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
CLEVELAND, April 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...
Completion of FDA Inspections Marks Progress Towards PDUFA DateRelated Stocks: ABEO...
Related Stocks: NAS:ABEO...
This indicator may be signaling that ABEO's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
- FDA completed Pre-License Inspection of Abeona's Cleveland manufacturing facility, as well as inspection of clinical trial sites for pz-cel pivotal Phase 3 VIITAL study -CLEVELAND, March 18, 2024...
This is a Bearish indicator signaling ABEO's price could decline from here. Traders may explore shorting the stock or put options...